APVO Projected Dividend Yield
Aptevo Therapeutics Inc ( NASDAQ : APVO )Aptevo Therapeutics is a clinical-stage, research and development biotechnology company focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. Co.'s lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, were developed using Co.'s ADAPTIR™ modular protein technology platform. Co.'s preclinical candidate APVO442 was developed using its ADAPTIR-FLEX™ modular protein technology platform. Co.'s ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of improving the human immune system against cancer cells. 20 YEAR PERFORMANCE RESULTS |
APVO Dividend History Detail APVO Dividend News APVO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |